Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 2/20 | 1.00 |
| ▸ | PDE6D | O43924 | 2/20 | 1.00 |
| ▸ | PDE8A | O60658 | 2/20 | 1.00 |
| ▸ | PDE5A | O76074 | 2/20 | 1.00 |
| ▸ | PDE9A | O76083 | 2/20 | 1.00 |
| ▸ | PDE8B | O95263 | 2/20 | 1.00 |
| ▸ | PDE6A | P16499 | 2/20 | 1.00 |
| ▸ | PDE6G | P18545 | 2/20 | 1.00 |
| ▸ | PDE4A | P27815 | 2/20 | 1.00 |
| ▸ | PDE6B | P35913 | 2/20 | 1.00 |
| ▸ | PDE6C | P51160 | 2/20 | 1.00 |
| ▸ | PDE1A | P54750 | 2/20 | 1.00 |
| ▸ | PDE1B | Q01064 | 2/20 | 1.00 |
| ▸ | PDE4B | Q07343 | 2/20 | 1.00 |
| ▸ | PDE4C | Q08493 | 2/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 2/20 | 1.00 |
| ▸ | PDE3B | Q13370 | 2/20 | 1.00 |
| ▸ | PDE7A | Q13946 | 2/20 | 1.00 |
| ▸ | PDE6H | Q13956 | 2/20 | 1.00 |
| ▸ | PDE1C | Q14123 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29379322 | 0.85 | PDE10A (0.74) | PDE2APDE6DPDE8APDE5APDE9A | |
| SCHEMBL30728010 | 0.82 | PDE2A (0.70) | PDE2APDE6DPDE8APDE5APDE9A | |
| SCHEMBL7268354 | 0.77 | PDE3B (0.62) | PDE2APDE6DPDE8APDE5APDE9A | |
| SCHEMBL971019 | 0.76 | PDE3B (0.61) | PDE2APDE6DPDE8APDE5APDE9A | |
| SCHEMBL7270195 | 0.76 | PDE4A (0.61) | PDE2APDE6DPDE8APDE5APDE9A | |
| SCHEMBL7269649 | 0.75 | PDE3B (0.58) | PDE2APDE6DPDE8APDE5APDE9A | |
| SCHEMBL7268431 | 0.75 | PDE4A (0.58) | PDE2APDE6DPDE8APDE5APDE9A | |
| SCHEMBL972979 | 0.73 | PDE10A (0.57) | PDE2APDE6DPDE8APDE5APDE9A | |
| SCHEMBL17817682 | 0.72 | PDE2A (0.56) | PDE2APDE6DPDE8APDE5APDE9A | |
| SCHEMBL9052411 | 0.71 | POLB (0.55) | PDE2APDE6DPDE8APDE5APDE9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040087599-A1 | cGMP-PDE inhibitors for the treatment of erectile dysfunction | PFIZER INC | 2004-05-06 | — | — | US | claimed |
| US-6469016-B1 | VAGINAL, VULVAR AND/OR URETHRAL ADMINISTRATION OF A PHARMACEUTICAL FORMULATION CONTAINING A VASOACTIVE AGENT TO INCREASE VAGINAL LUBRICATION | VIVUS, INC. | 2002-10-22 | — | — | US | claimed |
| US-20010044441-A1 | 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-one cGMP-PDE inhibitors for the treatment of erectile dysfunction | CAMPBELL SIMON FRASER (GB) | 2001-11-22 | — | — | US | claimed |
| US-20120245134-A1 | ANDROGEN PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING DEPRESSION | DUDLEY ROBERT E (US) | 2012-09-27 | — | — | US | disclosed |
| US-8263555-B2 | Use of bradykinin and related B2R agonists to treat ocular hypertension and glaucoma | ALCON RESEARCH, LTD. (US) | 2012-09-11 | — | — | US | disclosed |
| US-8252793-B2 | Bradykinin receptor agonists and uses thereof to treat ocular hypertension and glaucoma | ALCON RESEARCH, LTD. (US) | 2012-08-28 | — | — | US | disclosed |
| US-20120065180-A1 | ANDROGEN PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING DEPRESSION | DUDLEY ROBERT E (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120058981-A1 | ANDROGEN PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING DEPRESSION | DUDLEY ROBERT E (US) | 2012-03-08 | — | — | US | disclosed |
| US-20120046285-A1 | BRADYKININ RECEPTOR AGONISTS AND USES THEREOF TO TREAT OCULAR HYPERTENSION AND GLAUCOMA | ASTELLAS PHARMA INC. (JP) | 2012-02-23 | — | — | US | disclosed |
| US-20120009152-A1 | NITRIC OXIDE DONORS FOR TREATMENT OF DISEASE AND INJURY | NIH - DEITR | 2012-01-12 | — | — | US | disclosed |
| US-20110306582-A1 | ANDROGEN PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING DEPRESSION | DUDLEY ROBERT E (US) | 2011-12-15 | — | — | US | disclosed |
| US-20010051656-A1 | Co-administration of a prostaglandin and an androgenic agent in the treatment of female sexual dysfunction | PLACE VIRGIL A (US) | 2001-12-13 | — | — | US | disclosed |
| US-20010044441-A1 | 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-one cGMP-PDE inhibitors for the treatment of erectile dysfunction | CAMPBELL SIMON FRASER (GB) | 2001-11-22 | — | — | US | disclosed |
| US-6306841-B1 | NITROVASODILATOR SELECTED FROM SODIUM NITROPRUSSIDE, DIAZENIUM DIOLATE MOLSIDOMINE, LINSIDOMINE CHLORHYDRATE, S-NITROSOTHIOLS, ORGANIC NITRATES, PHARMACOLOGICALLY ACCEPTABLE SALTS, | ASIVI, LLC | 2001-10-23 | — | — | US | disclosed |
| US-6300335-B1 | UROGENITAL DISORDERS | PFIZER INC. | 2001-10-09 | — | — | US | disclosed |
| WO-2001019357-A2 | COMBINATION PREPARATION FOR THE TREATMENT OF SEXUAL DYSFUNCTION | BAYER AKTIENGESELLSCHAFT (DE) | 2001-03-22 | — | — | WO | disclosed |
| US-6156753-A | Local administration of type III phosphodiesterase inhibitors for the treatment of erectile dysfunction | VIVUS, INC. (US) | 2000-12-05 | — | — | US | disclosed |
| US-6127363-A | FOR TRANSURETHRAL OR TRANSDERMAL ADMINISTRATION OR INTRACAVERNOSAL INJECTION, KITS | VIVUS, INC. (US) | 2000-10-03 | — | — | US | disclosed |
| EP-1027057-A1 | TREATMENT OF FEMALE SEXUAL DYSFUNCTION | Asivi, LLC (US) | 2000-08-16 | — | — | EP | disclosed |
| WO-1999021562-A1 | TREATMENT OF FEMALE SEXUAL DYSFUNCTION | ASIVI, LLC (US) | 1999-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087599-A1 | cGMP-PDE inhibitors for the treatment of erectile dysfunction | PDE3A, PDE5A, PDE2A | PDE2A 3/4885PDE6D 24/4885PDE8A 30/4885 |
| US-20010044441-A1 | 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-one cGMP-PDE inhibitors for the treatment of erectile dysfunction | PDE3A, PDE2A, PDE3B | PDE2A 2/4885PDE6D 22/4885PDE8A 28/4885 |
| US-20120046285-A1 | BRADYKININ RECEPTOR AGONISTS AND USES THEREOF TO TREAT OCULAR HYPERTENSION AND GLAUCOMA | BDKRB2, BDKRB1, PTGIR | PDE2A 286/4885PDE6D 545/4885PDE8A 524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.